Clinical Results of Secondary Hormonal Treatment
Prostate cancer (PCa) is one of the leading malignant causes of death in men globally, with an incidence of 1,095,000 new cases diagnosed each year causing 307,000 cancer-specific deaths in 2012 . Many patients with PCa can be cured with local treatments, but approximately one-third of them will ultimately become a progressive disease, which will be characterized by increasing prostate-specific antigen (PSA) levels. Androgen deprivation therapy (ADT) including surgical or medical castration has been regarded as primary systemic therapy for metastatic PCa for more than 50 years. Surgical castration is the traditional treatment option which means bilateral orchiectomy. Nowadays, medical castration with gonadotropin-releasing hormone (GnRH) analogues and/or antiandrogen which suppresses testosterone production is the most common option in primary ADT.
- 1.IARC: GLOBOCAN. In: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx International Agency for Research on Cancer, 2012.
- 8.Fossa S, Slee PT, Brausi M, Horenblas S, Hall R, Hetherington J, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol. 2001;19(1):62–71.CrossRefPubMedGoogle Scholar
- 24.Almassi N, Reichard C, Li J, Russell C, Perry J, Ryan CJ, et al. HSD3B1 and response to a nonsteroidal CYP17A1 inhibitor in castration-resistant prostate cancer. JAMA Oncol. 2017;Google Scholar
- 27.Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol. 2000;18(7):1440–50.CrossRefPubMedGoogle Scholar